January 30, 2015 12:12 AM ET

Pharmaceuticals

Company Overview of Hydra Biosciences, Inc.

Company Overview

Hydra Biosciences, Inc., a biopharmaceutical company, engages in the identification and development of therapeutic agents that treat pain, inflammation, anxiety, renal, and pulmonary diseases. The company was founded in 2001 and is based in Cambridge, Massachusetts.

45 Moulton Street

Cambridge, MA 02138

United States

Founded in 2001

Phone:

617-494-5230

Fax:

617-494-5245

Key Executives for Hydra Biosciences, Inc.

Chief Executive Officer
Age: 55
Scientific Co-Founder and Member of Scientific Advisory Board - Cardiac Regeneration
Scientific Co-Founder and Member of Scientific Avisory Board - Cardiac Regeneration
Scientific Co-Founder and Member of Scientific Advisory Board - Cardiac Regeneration
Interim Chief Financial Officer
Compensation as of Fiscal Year 2014.

Hydra Biosciences, Inc. Key Developments

Hydra Biosciences, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 02:45 PM

Hydra Biosciences, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-13-2015 02:45 PM. Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States. Speakers: Russell H. Herndon, Chief Executive Officer, President and Director.

Hydra Biosciences, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 10:00 AM

Hydra Biosciences, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 10:00 AM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: Russell H. Herndon, Chief Executive Officer, President and Director.

Hydra Biosciences, Inc. and Boehringer Ingelheim GmbH Announce Collaboration to Develop Small-Molecule Inhibitors for the Treatment of Central Nervous System Diseases and Disorders

Hydra Biosciences, Inc. and Boehringer Ingelheim GmbH announced that they have entered into collaboration to research and develop small-molecule TRPC4/5 inhibitors for the treatment of central nervous system (CNS) diseases and disorders. Under the terms of the collaboration agreement, the companies will work together to identify and advance candidate inhibitors. Boehringer Ingelheim is responsible for the global development and commercialization of the inhibitors that come from the collaboration. Hydra will receive an upfront payment, additional research funding, and is eligible to receive milestone payments and tiered royalty payments on future product sales.

Similar Private Companies By Industry

Company Name Region
Curry Pharmaceuticals, Inc. United States
Barr Laboratories, Inc. United States
Zen Enterprises, LLC United States
HealthAsure, Inc. United States
Alexion Antibody Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Hydra Biosciences, Inc., please visit www.hydrabiosciences.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.